Biopharma Co. Accused Of Lying To Investors About FDA Hold

By Emilie Ruscoe · August 8, 2022, 8:15 PM EDT

An investor in biotherapeutics company Kiromic BioPharma Inc. has launched a proposed class action accusing the company and its leadership of touting prospects for two drug candidates ahead of a 2021...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

IN RE KIROMIC BIOPHARMA, INC. SECURITIES LITIGATION

Case Number

1:22-cv-06690

Court

New York Southern

Nature of Suit

Securities/Commodities

Date Filed

August 05, 2022